Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL777730 | 0.84 | HPGD (0.47) | HPGDMYCERCC5FEN1FLT1 | |
| SCHEMBL4390528 | 0.84 | ALDH1A1 (0.46) | HPGDTSHRSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6262061 | 0.83 | ESR1 (0.45) | HPGDMYCHTTTSHRKDM4E | |
| SCHEMBL776932 | 0.83 | HPGD (0.46) | HPGDMYCERCC5FEN1FLT1 | |
| SCHEMBL20543307 | 0.81 | MYC (0.48) | HPGDMYCERCC5FEN1FLT1 | |
| SCHEMBL7451599 | 0.81 | FLT1 (0.46) | HPGDMYCERCC5FEN1FLT1 | |
| SCHEMBL776165 | 0.79 | TSHR (0.48) | HPGDMYCERCC5FEN1FLT1 | |
| SCHEMBL777052 | 0.78 | HPGD (0.46) | HPGDMYCERCC5FEN1FLT1 | |
| Toluic Acid SCHEMBL23044119 | 0.77 | ALDH1A1 (0.53) | HPGDMYCERCC5FEN1HTT | |
| SCHEMBL3629126 | 0.76 | HPGD (0.41) | HPGDMYCERCC5FEN1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0364923-B1 | MESOMORPHIC COMPOUND, LIQUID CRYSTAL COMPOSITION CONTAINING SAME AND LIQUID CRYSTAL DEVICE USING SAME | CANON KABUSHIKI KAISHA (JP) | 1993-07-28 | — | — | EP | claimed |
| EP-0114043-B1 | DYE MIXTURES AND THEIR USE IN THE DYEING OF PAPER | BAYER AG (DE) | 1986-09-10 | — | — | EP | claimed |
| EP-0114043-A2 | Dye mixtures and their use in the dyeing of paper | BAYER AG (DE) | 1984-07-25 | — | — | EP | claimed |
| EP-2743262-B1 | Method for Obtaining a Triazine Compound with at least one Tertiary Amino Group | BOREALIS AGROLINZ MELAMINE (AT) | 2016-04-27 | — | — | EP | disclosed |
| EP-2743262-A1 | Method for Obtaining a Triazine Compound with at least one Tertiary Amino Group | Borealis Agrolinz Melamine GmbH (AT) | 2014-06-18 | — | — | EP | disclosed |
| US-20100240764-A1 | Use of S-Clenbuterol | EUCRO EUROPEAN CONTRACT RESEARCH GMBH & CO. KG (DE) | 2010-09-23 | — | — | US | disclosed |
| EP-1754474-A1 | Use of S-Clenbuterol | Eucro European Contract Research GmbH & Co. KG (DE) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006082046-A1 | USE OF S-CLENBUTEROL | EUCRO EUROPEAN CONTRACT RESEARCH GMBH & CO. KG (DE) | 2006-08-10 | — | — | WO | disclosed |
| EP-0114043-B1 | DYE MIXTURES AND THEIR USE IN THE DYEING OF PAPER | BAYER AG (DE) | 1986-09-10 | — | — | EP | disclosed |
| US-4521217-A | BLUE COLOR | BAYER AKTIENGESELLSCHAFT (DE) | 1985-06-04 | — | — | US | disclosed |
| EP-0114043-A2 | Dye mixtures and their use in the dyeing of paper | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240764-A1 | Use of S-Clenbuterol | CHRNB2, CHRNB3, CHRNB4 | HPGD 1122/4885MYC 4851/4885ERCC5 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.